Teriparatide in the treatment of osteoporosis

Jeffrey Stroup, Michael P. Kane, Asim M. Abu-Baker

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Purpose. The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed. Summary. Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen-receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost-effective in selected patients. Conclusion. Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.

Original languageEnglish
Pages (from-to)532-539
Number of pages8
JournalAmerican Journal of Health-System Pharmacy
Volume65
Issue number6
DOIs
StatePublished - 15 Mar 2008

Fingerprint

Teriparatide
Osteoporosis
Therapeutics
Bone Density Conservation Agents
Selective Estrogen Receptor Modulators
Anabolic Agents
Costs and Cost Analysis
Muscle Cramp
Osteoporotic Fractures
Femur Neck
Diphosphonates
Calcitonin
Dizziness
Bone Density
Nausea
Headache
Leg
Estrogens
Spine
Clinical Trials

Keywords

  • Costs
  • Fractures
  • Hormones
  • Mechanism of action
  • Osteoporosis
  • Post-menopause
  • Teriparatide
  • Toxicity

Cite this

Stroup, Jeffrey ; Kane, Michael P. ; Abu-Baker, Asim M. / Teriparatide in the treatment of osteoporosis. In: American Journal of Health-System Pharmacy. 2008 ; Vol. 65, No. 6. pp. 532-539.
@article{513969cf71bc401f874bd602f36af5f8,
title = "Teriparatide in the treatment of osteoporosis",
abstract = "Purpose. The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed. Summary. Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen-receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost-effective in selected patients. Conclusion. Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.",
keywords = "Costs, Fractures, Hormones, Mechanism of action, Osteoporosis, Post-menopause, Teriparatide, Toxicity",
author = "Jeffrey Stroup and Kane, {Michael P.} and Abu-Baker, {Asim M.}",
year = "2008",
month = "3",
day = "15",
doi = "10.2146/ajhp070171",
language = "English",
volume = "65",
pages = "532--539",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "6",

}

Teriparatide in the treatment of osteoporosis. / Stroup, Jeffrey; Kane, Michael P.; Abu-Baker, Asim M.

In: American Journal of Health-System Pharmacy, Vol. 65, No. 6, 15.03.2008, p. 532-539.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Teriparatide in the treatment of osteoporosis

AU - Stroup, Jeffrey

AU - Kane, Michael P.

AU - Abu-Baker, Asim M.

PY - 2008/3/15

Y1 - 2008/3/15

N2 - Purpose. The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed. Summary. Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen-receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost-effective in selected patients. Conclusion. Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.

AB - Purpose. The efficacy, safety, and cost of teriparatide in the treatment of osteoporosis are reviewed. Summary. Osteoporosis is a leading cause of fractures in women and men but is underdiagnosed and undertreated. Antiresorptive therapies (calcitonin, estrogen, bisphosphonates, and selective estrogen-receptor modulators) have historically been used to treat this condition. Teriparatide (recombinant human parathyroid hormone) is an anabolic agent labeled for use in postmenopausal women and men with osteoporosis who are at high risk for fractures. Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density. Teriparatide is expensive but may be cost-effective in selected patients. Conclusion. Teriparatide offers a therapeutic option for patients at high risk of an osteoporotic fracture and for patients who are intolerant of or unresponsive to antiresorptive therapy.

KW - Costs

KW - Fractures

KW - Hormones

KW - Mechanism of action

KW - Osteoporosis

KW - Post-menopause

KW - Teriparatide

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=41049084972&partnerID=8YFLogxK

U2 - 10.2146/ajhp070171

DO - 10.2146/ajhp070171

M3 - Review article

C2 - 18319498

AN - SCOPUS:41049084972

VL - 65

SP - 532

EP - 539

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 6

ER -